<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="297">
  <stage>Registered</stage>
  <submitdate>26/08/2005</submitdate>
  <approvaldate>5/09/2005</approvaldate>
  <actrnumber>ACTRN12605000289617</actrnumber>
  <trial_identification>
    <studytitle>An exploration of the immunomodulatory, anti-inflammatory and antioxidant activities of bovine lactoferrin in healthy males (a pilot study)</studytitle>
    <scientifictitle>An exploration of the immunomodulatory, anti-inflammatory and antioxidant activities of bovine lactoferrin in healthy males (a pilot study)</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Immune system</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Normal development and function of the immune system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Day 8-14 100mg bovine lactoferrin 100mg calcium phosphate with excipient magnesium stearate Day 15-21 200mg bovine lactoferrin with excipient magnesium stearate.</interventions>
    <comparator>Day 1-7 Placebo containing 200mg calcium phosphate with excipient magnesium stearate</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>In vivo changes in Lymphocyte Subset Counts including Mature T Cells (CD3+), B Cells (CD19+)</outcome>
      <timepoint>Days 1, 8, 10, 15, 17, 22</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>In vivo changes in Lymphocyte Subset Counts including Helper T cells (CD3+CD4+)</outcome>
      <timepoint>Days 1, 8, 10, 15, 17, 22</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>In vivo changes in Lymphocyte Subset Counts including Cytotoxic T Cells (CD3+CD8+)</outcome>
      <timepoint>Days 1, 8, 10, 15, 17, 22</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>In vivo changes in Lymphocyte Subset Counts including Natural Killer Cells (CD3-CD16+and/orCD56+)</outcome>
      <timepoint>Days 1, 8, 10, 15, 17, 22</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>In vivo changes in Non-Specific Immune Response including Natural Killer cell cytotoxicity</outcome>
      <timepoint>Days 1, 8, 10, 15, 17, 22</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>In vivo changes in Specific Immune Response including: 
* Activation of T-lymphocytes (CD4 and CD8) 
* Production of the following six cytokines: 
* IL-2, TNFá and IFNã predominantly regulating cell-mediated immune response 
* IL-4, IL-6 and IL-10 predominantly regulating humoral immune response</outcome>
      <timepoint>All measured weekly during the study.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In vivo changes in Serum oxygen radical antioxidant capacity (ORAC).</outcome>
      <timepoint>All measured weekly during the study.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Individuals willing to cease all medications over the course of the study, excluding medications for acute conditions such as pain or dyspepsia.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Individual taking antioxidant medications and /or supplements. Individuals with poor venous access. Individuals with auto-immune disorders. Individuals with diabetes. Individuals taking immune suppressant drugsÃ. Individuals taking cytokine or interferon therapy. Individuals taking Echinacea or other immune stimulating herbs. Individuals who smoke cigarettes or any other drug. Individuals with clinically abnormal liver function tests at baseline. Individuals unwilling to have blood taken 7 times during the study. Individuals unwilling to comply with the study protocols. Individuals with any other condition that in the opinion of the researchers could compromise the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>10/05/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Blackmores</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Blackmores</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study explored the degree of safety and efficacy of a bovine lactoferrin supplement on healthy males by evaluating the in vivo and ex vivo changes of antioxidant and various immune cell functions.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Cross University Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Queensland Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joan O'Connor</name>
      <address>Australian Centre for Complementary Medicine Education and Research (ACCMER)
PO Box 157
Lismore NSW 2480</address>
      <phone>+61 2 66203649</phone>
      <fax>+61 2 66203307</fax>
      <email>joconnor@scu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Stephen Myers</name>
      <address>Australian Centre for Complementary Medicine Education and Research (ACCMER)
PO Box 157
Lismore NSW 2480</address>
      <phone>+61 2 66203403</phone>
      <fax>+61 2 66203307</fax>
      <email>smyers@scu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>